ES2628935T3 - N4 quelantes conjugados - Google Patents

N4 quelantes conjugados Download PDF

Info

Publication number
ES2628935T3
ES2628935T3 ES05763654.0T ES05763654T ES2628935T3 ES 2628935 T3 ES2628935 T3 ES 2628935T3 ES 05763654 T ES05763654 T ES 05763654T ES 2628935 T3 ES2628935 T3 ES 2628935T3
Authority
ES
Spain
Prior art keywords
compound
mmol
wide
tert
nch2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05763654.0T
Other languages
English (en)
Spanish (es)
Inventor
Anthony E STOREY
Harry Wadsworth
Nigel A POWELL
Philip Duncanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Application granted granted Critical
Publication of ES2628935T3 publication Critical patent/ES2628935T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES05763654.0T 2004-07-19 2005-07-19 N4 quelantes conjugados Expired - Lifetime ES2628935T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0416062 2004-07-19
GBGB0416062.8A GB0416062D0 (en) 2004-07-19 2004-07-19 Improved N4 chelator conjugates
PCT/GB2005/002807 WO2006008496A2 (en) 2004-07-19 2005-07-19 Improved n4 chelator conjugates

Publications (1)

Publication Number Publication Date
ES2628935T3 true ES2628935T3 (es) 2017-08-04

Family

ID=32893775

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05763654.0T Expired - Lifetime ES2628935T3 (es) 2004-07-19 2005-07-19 N4 quelantes conjugados

Country Status (14)

Country Link
US (1) US7767796B2 (enExample)
EP (1) EP1768708B1 (enExample)
JP (1) JP5557425B2 (enExample)
KR (2) KR20070034064A (enExample)
CN (1) CN101128219B (enExample)
AU (1) AU2005263942B2 (enExample)
BR (1) BRPI0513456A (enExample)
CA (1) CA2573384C (enExample)
ES (1) ES2628935T3 (enExample)
GB (1) GB0416062D0 (enExample)
MX (1) MX2007000744A (enExample)
NO (1) NO20070348L (enExample)
RU (1) RU2360701C2 (enExample)
WO (1) WO2006008496A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101732736B (zh) * 2009-12-02 2012-04-04 北京师范大学 制备锝-99m标记的DTPA-LSA的药盒及制备方法和应用
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
GB201016206D0 (en) * 2010-09-27 2010-11-10 Ge Healthcare Ltd Apoptosis imaging agents
RU2465011C1 (ru) * 2011-04-27 2012-10-27 Общество с ограниченной ответственностью "ИНТЕРА-МЕД" Радиофармацевтический препарат для диагностики меланомы и ее метастазов
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
RU2655392C1 (ru) * 2017-03-02 2018-05-28 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский политехнический университет" Способ получения комплекса технеция-99м с октреотидом для диагностики нейроэндокринных опухолей
CN112105393A (zh) 2018-05-16 2020-12-18 爱默蕾大学 苯乙烯基苯并噻唑衍生物及在成像中的用途
US20250215027A1 (en) * 2021-08-11 2025-07-03 Cancer Research Technology Limited Diphosphine compounds and complexes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175343A (en) * 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
ATE66469T1 (de) * 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US5242679A (en) * 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5053493A (en) * 1987-04-02 1991-10-01 Centocor Cardiovascular Imaging Partners, L.P. Method for labeling antibodies with a metal ion
JPH02504387A (ja) * 1987-04-02 1990-12-13 セントカー・カーデイオバスキユラー・イメージング・パートナーズ・エルピー 金属イオンで抗体を標識付けする方法
US4952393A (en) * 1987-04-02 1990-08-28 The General Hospital Corporation Organ infarct imaging with technetium labelled glucarate
US5489425A (en) * 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
NO940080L (no) * 1993-01-12 1994-07-13 Sandoz Ag Polypeptider , fremgangsmåte for deres fremstilling og farmasöytiske preparater derav
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
CA2232411A1 (en) * 1995-09-18 1997-03-27 Mallinckrodt Medical, Inc. (radio) labelled biotin derivatives
GR1003661B (el) * 2000-05-25 2001-09-05 Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος"... ΣΥΝΘΕΣΗ, ΒΙΟΛΟΓΙΚΗ ΚΑΙ ΠΡΟΚΛΙΝΙΚΗ ΑΞΙΟΛΟΓΗΣΗ ΑΝΑΛΟΓΩΝ ΤΗΣ (D-Phe6, Leu-NHEt13, des-Met14)-ΒΟΜΒΕΣΙΝΗΣ (6-14)ΤΡΟΠΟΠΟΙΗΜΕΝΩΝ ΜΕ ΠΑ ΡΑΓΩΓΑ ΤΟΥ 1,4,8,11-ΤΕΤΡΑΑΖΑΕΝΔΕΚΑΝΙΟΥ(1,4,8,11-TETRAAZAUNDECAN E)ΚΑΙ ΕΠΙΣΗΜΑΣΜΕΝΩΝ ΜΕ ΤΕΧΝΗΤΙΟ-99M- ΓΙΑ ΕΦΑΡΜΟΓΗ ΣΤΗΝ ΟΓΚΟΛΟΓ
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
CN1622830A (zh) * 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
US7785566B2 (en) * 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds
US7431914B2 (en) * 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
CN1925876A (zh) * 2004-03-04 2007-03-07 通用电气医疗集团股份有限公司 用于诊断和治疗的血管紧张素肽类似物和螯合剂的缀合物

Also Published As

Publication number Publication date
AU2005263942B2 (en) 2009-02-26
EP1768708A2 (en) 2007-04-04
MX2007000744A (es) 2007-06-25
CN101128219B (zh) 2012-06-20
CN101128219A (zh) 2008-02-20
CA2573384C (en) 2013-09-10
US7767796B2 (en) 2010-08-03
US20080131368A1 (en) 2008-06-05
KR20070034064A (ko) 2007-03-27
EP1768708B1 (en) 2017-05-17
CA2573384A1 (en) 2006-01-26
NO20070348L (no) 2007-02-16
GB0416062D0 (en) 2004-08-18
KR20130024963A (ko) 2013-03-08
AU2005263942A1 (en) 2006-01-26
WO2006008496A3 (en) 2006-07-27
BRPI0513456A (pt) 2008-05-06
JP2008510683A (ja) 2008-04-10
JP5557425B2 (ja) 2014-07-23
RU2360701C2 (ru) 2009-07-10
WO2006008496A2 (en) 2006-01-26
RU2007101515A (ru) 2008-08-27

Similar Documents

Publication Publication Date Title
AU2018382479B2 (en) PSMA ligands for imaging and endoradiotherapy
JP6169520B2 (ja) タンパク質薬剤接合体のための分枝リンカー
WO1999020626A1 (en) Folic acid derivatives
PT1904460E (pt) Ligandos aza multidentados capazes de complexar iões metálicos e sua utilização em diagnósticos e terapia
ES3048365T3 (en) Synthesis of prostate specific membrane antigen (psma) ligands
AU2020213892B2 (en) Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof
RU2697519C1 (ru) Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
RU2360701C2 (ru) Усовершенствованные конъюгаты n4 хелатообразующих агентов
EP3494999A1 (en) Psma ligands for imaging and endoradiotherapy
AU2020306219B2 (en) Cyclen based compounds, coordination compounds, peptides, pharmaceutical preparation, and use thereof
ES2338164T3 (es) Compuestos para la inhibicion de la apoptosis.
RU2841078C1 (ru) Лиганды, тропные к простатическому специфическому мембранному антигену и их применение для получения двойных конъюгатов с терапевтическими агентами на их основе для комбинированной терапии псма экспрессирующих опухолей
이원창 Development of PSMA-targeting ligands for theranostic applications in prostate cancer
RU2807076C2 (ru) Лиганды PSMA для визуализации и эндорадиотерапии
HK40031508B (en) Psma ligands for imaging and endoradiotherapy